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ABSTRACT 34 
 The recent development and spread of extensively (XDR) and totally resistant (TDR) 35 
strains of Mycobacterium tuberculosis, highlights the need for new antitubercular drugs. 36 
Protein synthesis inhibitors have played an important role in the treatment of tuberculosis 37 
(TB) starting with the inclusion of streptomycin in the first combination therapies.  Although 38 
the parenteral aminoglycosides are a key component in multidrug-resistant (MDR) TB 39 
therapy, the oxazolidinone, linezolid, is the only orally available protein synthesis inhibitor 40 
that is effective against TB. Herein, we show that small molecule inhibitors of aminoacyl-41 
tRNA synthetases (AARS), known to be excellent antibacterial protein synthesis targets, can 42 
be designed that are orally bioavailable and effective against M. tuberculosis in TB mouse 43 
infection models. We applied the oxaborole tRNA trapping (OBORT) mechanism, which was 44 
first developed to target fungal cytoplasmic leucyl-tRNA synthetase (LeuRS), to M. 45 
tuberculosis LeuRS.  X-ray crystallography was used to guide design of LeuRS inhibitors 46 
that have good biochemical potency and excellent whole cell activity against M. tuberculosis. 47 
Importantly, their good oral bioavailability translates into in vivo efficacy in both the acute 48 
and chronic mouse models of TB with comparable potency to the frontline drug isoniazid. 49 
50 
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INTRODUCTION 51 
 The aminoacyl-tRNA synthetases (AARS) are a family of essential enzymes that are 52 
required for protein synthesis in all cells (38). Although various family members have been 53 
targeted for the design of novel antibacterial (37) only the isoleucyl-tRNA synthetase 54 
inhibitor, mupirocin, is an FDA-approved antibiotic (36).  However, mupirocin is only 55 
approved for the topical treatment of staphylococcal and streptococcal skin infections (36) 56 
and M. tuberculosis is naturally resistant to this agent (31).  Leucyl-tRNA synthetase 57 
(LeuRS) is a class I AARS that has two active sites separated by a distance of 30 Å; a 58 
synthetic site that aminoacylates tRNALeu and an editing site that ensures the fidelity of 59 
translation by a proofreading mechanism (7, 10, 19, 26). Recently boron-containing 60 
compounds known as oxaboroles have been shown to inhibit LeuRS by the oxaborole tRNA 61 
trapping (OBORT) mechanism (29), which exploits the ability of the boron atom to bond to 62 
the cis-diols of the 3´-terminal adenosine nucleotide, Ade76, of tRNALeu.  The resulting 63 
covalent adduct traps the 3´-end of tRNALeu in the editing site in a non-productive complex, 64 
inhibiting leucylation and thereby protein synthesis (29). Here we report the discovery of 65 
novel 3-aminomethyl derivatives that have potent antitubercular activity. 66 
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MATERIALS AND METHODS 68 
Chemical Synthesis. Starting materials used were either available from commercial sources 69 
or prepared according to literature procedures and had experimental data in accordance with 70 
those reported.  The syntheses of the compounds are described in detail in the Supplementary 71 
Material. 72 
Expression, purification and crystallization of M. tuberculosis LeuRS editing domain.  A 73 
DNA fragment coding for the region G309 to I513 of M. tuberculosis LeuRS (Uniprot 74 
P67510) was cloned into pETM-11 using the NcoI and XdeI restriction sites (EMBL). The 75 
protein containing an N-terminal six-histidine tag was prepared and purified following a 76 
similar protocol as for the E. coli LeuRS (26), except that the nickel affinity chromatography 77 
was conducted at pH 8.0.  Protein was stored in buffer comprising 20 mM Tris-HCl (pH 7.4), 78 
100 mM NaCl, 5 mM MgCl2 and 5 mM 2-mercaptoethanol.  Crystallization was performed at 79 
20°C by the hanging drop vapor diffusion method.  The solutions for the ternary complexes 80 
were prepared with 10 mg/mL LeuRS, 5 mM AMP and 1 mM of the corresponding 81 
benzoxaborole compound (provided by Anacor Pharmaceuticals, Palo Alto, CA).  Initial 82 
crystals were obtained at 15 mg/mL LeuRS, 5 mM AMP and 1 mM of the corresponding 83 
benzoxaborole compound (provided by Anacor Pharmaceuticals, Palo Alto, CA).  Crystals 84 
were obtained by mixing 2 μL of this solution with 2 μL of reservoir solution containing 0.1 85 
M Bis-TRIS (pH 5.5), 22% (w/v) PEG 10000 and 0.2 M ammonium acetate. Quality and size 86 
of final diffracting crystal was improved by decreasing LeuRS concentration to 10 mg/mL 87 
and PEG 10000 to 17% (w/v).  The crystals were frozen directly in liquid nitrogen in the 88 
mother liquor containing 15% (v/v) ethylene glycol as a cryoprotectant. 89 
Structure determination and refinement.  All diffraction data sets were collected at the 90 
European Synchrotron Radiation Facility (ESRF, Grenoble, France). Data were integrated 91 
and scaled with the XDS suite (15). Further data analysis was performed with the CCP4 suite 92 
(3). The structure of the LeuRS:AMP-compound 6 complex was initially solved by molecular 93 
replacement with PHASER (22) using the E. coli LeuRS editing domain structure(20) (PDB 94 
2AJG) as a model. The model was improved by automatic building using ARP-wARP (28) 95 
and manual adjustments were made with COOT (9).  The structures of the complexes with 96 
the compounds 14 and 16 were solved using the editing domain of M. tuberculosis LeuRS 97 
(described above) as a model. All models were refined using REFMAC5 with anisotropic B-98 
factors. Structure quality was analyzed with MOLPROBITY(4) 99 
(http://molprobity.biochem.duke.edu/) and showed all residues in allowed regions (with 95.1-100 
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98.0% of residues in favored regions) for the different models. Figures were drawn with 101 
PYMOL (http://www.pymol.org/). 102 
Aminoacylation assay.  An N-terminal six histidine-tagged LeuRS from M. tuberculosis 103 
H37Rv, which was codon-optimized for E. coli (GenScript, Piscataway NJ, USA), was over-104 
expressed and purified according to Novagen (Madison, WI, USA) using an E. coli 105 
BL21(DE3) T7 RNA polymerase over-expression strain.  Experiments were performed in 96-106 
well microtiter plates, using 80 μL reaction mixtures containing 50 mM HEPES-KOH (pH 107 
8.0), 30 mM MgCl2 30 mM KCl, 13 μM L-[14C]leucine (306 mCi/mmol, Perkin-Elmer), 15 108 
µM total E. coli tRNA (Roche, Switzerland), 0.02% (w/v) BSA, 1 mM DTT, 0.2 pM LeuRS 109 
and 4 mM ATP at 300C.  Reactions were started by the addition of 4 mM ATP.  After 7 110 
minutes, reactions were quenched and tRNA was precipitated by the addition of 50 μL of 111 
10% (w/v) TCA and transferred to 96-well nitrocellulose membrane filter plates (Millipore 112 
Multiscreen HTS, MSHAN4B50).  Each well was then washed three times with 100 μL of 113 
5% TCA.  Filter plates were then dried under a heat lamp and the precipitated L-[14C]leucine 114 
tRNALeu were quantified by liquid scintillation counting using a Wallac MicroBeta Trilux 115 
model 1450 liquid scintillation counter (PerkinElmer, Waltham, MA, USA).  116 
IC50 determination. To determine the inhibitor concentration, which reduces enzyme 117 
activity by 50% (IC50), increasing concentrations of compound inhibitors that covered the 118 
IC50 value were incubated with LeuRS enzyme, tRNA and L-leucine for 20 minutes.  119 
Reactions were initiated by the addition of 4 mM ATP.  Reactions were stopped after 7 120 
minutes then precipitated and counted to quantify radioactivity.  IC50 values were determined 121 
using a 4-parameter logistic nonlinear regression model (Graphpad Software Inc. (La Jolla, 122 
CA, USA). 123 
Isothermal titration calorimetry (ITC) experiments. ITC experiments were performed at 124 
250C using an ITC200 system (MicroCal, GE Healthcare). The editing domain protein was 125 
dialyzed for 12 hours against the titration buffer (50 mM HEPES-KOH, 30 mM KCl and 30 126 
mM MgCl2, pH 8.0) at 40C. Protein solutions at 50 μM plus AMP at 10 mM in the 127 
calorimetric cell were titrated with the appropriate compound dissolved in dialysis buffer. 128 
Compound solutions at 1-5mM plus AMP at 10 mM were incubated at 37°C during 1 hour 129 
before titrations. The heat evolved after each ligand injection was obtained from the integral 130 
of the calorimetric signal. The resulting binding isotherms were analyzed by nonlinear least-131 
squares fitting of the experimental data to a single site model. Analysis of the data was 132 
performed using Microcal Origin software (OriginLab version 7). Experiments were 133 
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performed at least twice. The variability in the binding experiments was estimated to be 5% 134 
in the binding enthalpy; and 10% in both the binding affinity and the number of sites. 135 
Determination of minimum inhibitory concentration for M. tuberculosis. MIC 136 
determinations were mainly determined using resazurin (Alamar Blue) as an indicator for cell 137 
growth (6) with additional determinations as described by Ollinger et al (25). 138 
Selection of M. smegmatis ATCC 700084 single-step mutants. Resistant mutants to 139 
compound 1 were isolated on Middlebrook 7H10 medium plus 10% (v/v) oleic albumin 140 
dextrose catalase (OADC) supplement (Becton Dickinson) containing compound 1 at 4xMIC. 141 
Resistance was confirmed by measuring the mutants MIC value essentially as described by 142 
Collins et al (6). 143 
Selection of M. tuberculosis single-step mutants.  M. tuberculosis mutants resistant to 144 
compound 1 and 13 were isolated as described by Ioerger et al (14). Mutants were isolated on 145 
Middlebrook 7H10 medium plus 10% (v/v) OADC (Becton Dickinson) containing compound 146 
1 and 13 at 5X or 10X MIC99. Resistance was confirmed by measuring MIC99 on solid 147 
medium – defined as minimum concentration that inhibits 99% of CFU (34).  Genome 148 
sequencing and identification of polymorphisms were essentially carried out as described by 149 
by Ioerger et al (14).  In order to determine the rate of spontaneous resistant mutants, M. 150 
tuberculosis H37RV was grown at 37°C in fresh Middlebrook 7H9-ADC-Tween 80 to mid-151 
exponential phase and then diluted in fresh Middlebrook 7H9-ADC-Tween 80 to 5x108 152 
CFU/mL. Middlebrook 7H10-OADC plates with 4 and 10-fold MIC of each compound were 153 
inoculated with 108, 107, 106, and 105 CFU/plate, and the plates were incubated at 37°C for 3 154 
to 4 weeks. The frequency of appearance of resistant mutants was calculated, and isolated 155 
colonies were restreaked onto Middlebrook 7H10-OADC agar containing the drugs and on 156 
plates without the drug. 157 
Time-kill assay. Compounds were added at 20xMIC to a 10 mL exponential culture of M. 158 
tuberculosis H37Rv (~5x105 cfu/mL) in Middlebrook 7H9 with 10% (v/v) OADC and 0.05% 159 
(v/v) Tween-80. At specified time points, aliquots of cultures were withdrawn, serially 160 
diluted and plated on solid culture medium. Plates were then incubated at 37oC and CFU 161 
were counted after 3 to 4 weeks.  162 
In vitro cytotoxicity assay.  Vero epithelial cells (from African green monkey; ATCC CCL-163 
81) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 164 
fetal bovine serum (FBS) and maintained in a humidified incubator (370C, 5% CO2). Cells 165 
were dislodged with a cell scraper, collected by centrifugation, resuspended in fresh medium 166 
at ~106 cells/mL, dispensed into 96-well microtitre plates (100mL/well) and incubated for 167 
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18h at 370C. Two-fold serial dilutions of test compounds (800–0.4 mg/L) in DMEM with 168 
FBS were subsequently added and cells incubated for another 72h. From triplicate studies, 169 
the cytopathic effects of compounds were evaluated colorimetrically using the MTT cell 170 
proliferation assay (ATCC). IC50 data were obtained from dose–response curves plotted using 171 
Graphpad prism 5.  172 
Mitochondrial protein synthesis assay.  Human liver carcinoma derived HepG2 cell line 173 
was obtained from the ATCC (HB-8065).  HepG2 cells were grown in Dulbecco's Modified 174 
Eagle's medium containing 10% Fetal Calf Serum, 1 mM sodium pyruvate, 0.1 mM non 175 
essential amino acids and 50 units/mL penicillin-streptomycin at 370C with 5% CO2. HepG2 176 
cells were seeded in 96-well plates at 3000 cells/200 μL/well in cell culture medium. Cells 177 
were then grown in the presence of the compounds at 37 °C in 10% CO2 for 7 days in at least 178 
duplicate concentrations, with the medium and compounds being replaced on the fourth day. 179 
After 7 days the levels of SDHA and COX1 were determined by using the MitoSciencesTM 180 
In-Cell ELISA kit. Janus Green staining was used to determined cell viability after 7 days 181 
(In-cell ELISA kit, cat # MS643).  182 
Mouse pharmacokinetic analysis. The studies were conducted using female CD-1 for 183 
compounds 1, 11 and 12, while BALB/C mice were used for compound 13. Mice body 184 
weights were 19-28 g and on the morning of dosing, mice were split randomly into 3 dosing 185 
groups to receive test article by either tail-vein injection (IV) or oral gavage (PO). After 186 
dosing, blood samples were collected via cardiac puncture at specific time points (n=3 187 
mice/time point) through 24 hours (K2EDTA as anticoagulant) and processed for plasma. 188 
Antibiotic concentrations in the plasma samples were analysed by LC/MS/MS. The 189 
LC/MS/MS analysis was conducted using analyte/internal standard peak area methods. The 190 
minternal standard was AN3365 (13) and the instrument was a API4000 QTRAP (AB Sciex).  191 
The limit of quantitation (LOQ) was 1 or 2 ng/mL. Pharmacokinetic analyses of the mean 192 
plasma concentration-time profiles were performed using WinNonlin Pro version 5.2. A 193 
compartmental model was used for the IV data and non-compartmental model for PO data. 194 
The time-concentration curve after an IV dose showed a bi-exponential decline with first-195 
order elimination. Compound 1 and 13 were formulated in saline (0.9% w/v NaCl) at 7.5 196 
mg/mL and the pH adjusted to >5 by the addition of NaOH.  Compound 11 was formulated 197 
to 6.5 mg/mL in Water/Dimethylacetamide/EtOH (76/19/5) and the pH adjusted to >5 by the 198 
addition of NaOH. Compound 12 was formulated to 7.5 mg/mL in PEG300/PG/water 199 
(55/25/20) and the pH adjusted to >5 by the addition of NaOH. 200 
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Mouse plasma protein binding determination. Compounds were added to 1.5-mL aliquots 201 
of mouse plasma and plasma ultrafiltrate to the following concentrations: 1 µg/mL and 10 202 
µg/mL, and then incubated in a shaking water-bath at 37 °C for 15 minutes. Both samples 203 
were treated similarly and a 0.5-mL aliquot was removed from each tube and added to the 204 
filter reservoir of the Microcon® centrifugal filter devices (Ultracel YM-30, MWCO=30K 205 
Da, Bedford, MA). The devices were centrifuged at 1000 x g for 10 minutes and 100 µL of 206 
filtrate was transferred to the 96-well plate and diluted 5-fold. Ten-µL volumes of the 207 
samples were injected and analyzed with the LC/MS/MS system.  All samples were analysed 208 
in duplicate.  Quantitation was based on peak area ratio of analyte over internal standard and 209 
all integrations were performed with peak areas using Analyst version 1.4.1 (Applied 210 
Biosystems, Foster City, CA 94404, USA). Plasma protein binding was calculated, based on 211 
the following equation:   212 
Plasma Protein Binding (%) = (PeakAreaPlasmaUltrafiltrate
Spiked
− PeakAreaPlasma
Filtrate )
PeakAreaPlasmaUltrafiltrate
Spiked *100 213 
Murine model of acute TB infection using C57/BL GKO IFNγ mice.  Eight- to 10-week-214 
old female specific-pathogen-free C57BL/6-Ifngtm1ts mice (IFNγ gene-disrupted [GKO] 215 
mice) were purchased from Jackson Laboratories, Bar Harbor, ME. The mice were infected 216 
via a low-dose aerosol exposure with M. tuberculosis Erdman in a Middlebrook aerosol 217 
generation device (Glas-Col Inc., Terre Haute, IN) as described previously (18). One day 218 
post-aerosol, three mice were sacrificed to verify the uptake of 50 to 100 CFU of bacteria per 219 
mouse. Each treatment group consisted of five mice and treatment was started 10-13 days 220 
post-infection and continued for nine or fourteen consecutive days.  Five infected mice were 221 
sacrificed at the start of treatment as pretreatment controls.  Drugs were administered daily by 222 
oral gavage. Lungs were harvested 24 hours after the last administration and all lung lobes 223 
were aseptically removed, homogenized and frozen.  Homogenates were plated on 10% 224 
OADC-7H11 medium for 21 days at 37ºC. All animal studies strictly adhered to the protocols 225 
and regulations approved by their respective Animal Care and Use Committees of University 226 
of Illinois at Chicago and Colorado State University. 227 
Murine model of acute and chronic TB infection using C57/BL6J mice.  Specific 228 
pathogen-free, 8-10 week-old female C57BL/6 mice were purchased from Harlan 229 
Laboratories and were allowed to acclimate for one week. The experimental design for the 230 
acute assay has been previously described (30). In brief, for the acute assay, mice were 231 
intratracheally infected with 100,000 CFU/mouse (M. tuberculosis H37Rv strain). Products 232 
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were administered for 8 consecutive days starting one day after infection. For the chronic 233 
assay, mice were intratracheally infected with 100 CFU/mouse and the products administered 234 
daily (7 days a week) for 8 consecutive weeks starting 6 weeks after infection. Lungs were 235 
harvested 24 hours after the last administration. All lung lobes were aseptically removed, 236 
homogenized and frozen.  Homogenates were plated on 10% OADC-7H11 medium and 237 
incubated for 21 days at 37ºC. The viable colony forming units were converted to logarithms, 238 
which were then evaluated by a one-way analysis of variance, followed by a multiple-239 
comparison analysis of variance by a one-way Tukey test (SigmaStat software program). 240 
Differences were considered significant at the 95% level of confidence.  All animal studies 241 
were ethically reviewed and carried out in accordance with European Directive 2010/63/EU 242 
and the GSK Policy on the Care, Welfare and Treatment of Animals. 243 
Murine model of chronic TB infection using BALB/c mice.  Six- to 8-week-old female 244 
specific-pathogen-free immunocompetent BALB/c mice (Charles River, Wilmington, MA) 245 
were infected via a low-dose aerosol exposure to M. tuberculosis Erdman as described (18). 246 
One day post-aerosol, three mice from each run were sacrificed to verify the uptake of 50 to 247 
100 CFU of bacteria per mouse. Each group consisted of five to six mice at each time point. 248 
Treatment was started 3 weeks post-infection and continued for 12 weeks. Five infected mice 249 
were sacrifice at the start of treatment as pretreatment controls. Drugs were administered 5 250 
days per week by oral gavage, for four weeks. Lungs were harvested 72 hours after the last 251 
administration. All lung lobes were aseptically removed, homogenized and frozen.  252 
Homogenates were plated on 10% OADC-7H11 medium and incubated for 21 days at 37ºC. 253 
All animal studies strictly adhered to the protocols and regulations approved by Colorado 254 
State University’s Animal Care and Use Committee. 255 
256 
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RESULTS AND DISCUSSION 257 
Discovery of antitubercular LeuRS inhibitors. A focus library of 20 benzoxaboroles was 258 
initially screened against M. tuberculosis H37Rv, which yielded AN3016 and AN3017 with 259 
minimal inhibitory concentration (MIC) of 1 µg/mL and 1.8 µg/mL and LeuRS half-maximal 260 
inhibitory concentration (IC50) of 3.5 µM and 0.64 µM, respectively (Fig. 1).  When we 261 
combined both the 3-aminomethyl and the 7-ethoxy substitutions in one moiety, compound 1, 262 
it gave significantly better activity with a LeuRS IC50 of 0.28 µM and an MIC of 0.26 µg/mL 263 
(Fig. 1).  To confirm that compound 1 was targeting LeuRS in the cell, we obtained resistant 264 
mutants of M. tuberculosis H37Rv and Mycobacterium smegmatis ATCC 700084. The leuS 265 
gene, which codes for LeuRS, was sequenced from selected resistant mutants and mutations 266 
were found in both organisms, which was consistent for an OBORT LeuRS inhibitor (Fig. 2 267 
and Table 1). Therefore, we progressed compound 1 into an in vivo mouse pharmacokinetic 268 
study to determine suitability for testing in an acute TB mouse model.  Compound 1 was 269 
dosed by oral administration (PO) at 30 mg/kg, which yielded an area under the curve over 270 
24 hrs (AUC0-24) of 15 h*µg/mL with a maximum plasma level (Cmax) of 4.33 µg/mL and 271 
oral bioavailability of 55% (data not shown). Since the existing in vivo efficacy mouse model 272 
used M. tuberculosis Erdman and not M. tuberculosis H37Rv, the MIC of compound 1 was 273 
confirmed against the Erdman strain as well as some drug-resistant isolates (Table 2). The M. 274 
tuberculosis Erdman MIC value was 0.127 µg/mL, which was not affected by resistance 275 
mechanisms to rifampin, isoniazid or streptomycin.  Compound 1 was then tested in a 276 
BALB/c acute model of TB dosed at 100 mg/kg twice-a-day (BID) for 3 weeks with weekend 277 
drug holidays. The control drug, PA-824 (Pretomanid) (35), was dosed at 100 mg/kg once-a-278 
day (QD), which gave a 1.9 log10 reduction in colony forming units (CFU) from mouse lungs 279 
compared to only a 0.4 log10 reduction in CFU for compound 1 (data not shown).  Therefore, 280 
we separated the two enantiomers in compound 1 by chiral HPLC and determined their 281 
activities (Fig. 1). The active enantiomer was the (S)-isomer, compound 2, which had a 282 
LeuRS IC50 of 0.13 µM and an MIC of 0.13 µg/mL, while the (R)-isomer was barely active 283 
with an IC50 of 21 µM.  The active enantiomer, compound 2, was then tested at 200 mg/kg 284 
BID for 9 days in the acute TB model using an IFN-γ gene knock-out (GKO) mouse (17), 285 
which showed a 2 log10 reduction in lung CFU and a 1.5 log10 reduction in spleen CFU 286 
compared to the control mice (Fig. 3).  However, this was not as good as the frontline drug 287 
isoniazid (INH), which gave a 2.8 and 3.4 log10 reduction in CFU from lungs and spleen, 288 
respectively, when dosed at 25 mg/kg.  289 
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M. tuberculosis LeuRS inhibitor co-crystalization.  In order to improve potency we 290 
performed structural and biophysical studies to understand the binding mode of these novel 291 
3-aminomethyl benzoxaboroles to M. tuberculosis LeuRS. Crystallization trials with different 292 
editing domain constructs of M. tuberculosis LeuRS were attempted in the presence of 293 
compound 2 with either AMP or longer nucleotides such as CytAde or CytCytAde, which 294 
might act as surrogates for the 3´-end of the tRNA acceptor stem (32). An editing domain 295 
construct encompassing residues G309-I513 gave co-crystals with compound 2 and AMP that 296 
diffracted to 1.3 Å resolution, which permitted structure determination (Fig. 4A, 4B and 297 
Table S1). Compound 2 forms a bidentate covalent adduct with AMP (Fig. 4B), which 298 
mimics Ade76 of the tRNA acceptor end (13, 19, 26). The amino acid residues, T336-T337, 299 
of the threonine-rich region provides multiple H-bonding interactions to the covalent adduct, 300 
and L432 and Y435 of the AMP binding loop have extensive H-bonding and hydrophobic 301 
contacts with AMP (Fig. 4B). In addition, the amino group of compound 2 makes three key 302 
interactions with the carboxylic acid side chains of D447 and D450 and the carbonyl of 303 
M441. The 7-ethoxy enables not only a new interaction to R449 but also packs with the 304 
Ade76 ribose, thus further stabilizing the boron-tRNA adduct (Fig. 4B).  Superposition of the 305 
compound 2 adduct bound structure with that of the E. coli LeuRS editing domain with 306 
methionine bound (20) shows that the 3-aminomethyl benzoxaborole moiety occupies the 307 
same position as the non-cognate amino acid (Fig. 4C). Although this moiety mimics the 308 
interactions established by the amino and the oxygen carbonyl groups of methionine, it lacks 309 
atoms at the positions of the Sδ-Cε atoms of methionine (Fig. 4C), which suggests that there is 310 
additional space to make further interactions.   311 
SAR of potent antituberculars.  Several derivatives were synthesized with different 312 
substitutions at position 4 as well as at positions 5 and 6 to explore this hypothesis (Fig. 1).  313 
The halogen substitutions 5-Cl (compound 5) and 6-F (compound 7) were not well tolerated 314 
with LeuRS IC50 values worse than the original compound 1 and MIC values of 1.1 µg/mL or 315 
greater. The most potent analogs were compounds with halogen substitutions at position 4, 316 
bromo (compound 11), chloro (compound 4) and fluoro (compound 6), which improved MIC 317 
values more than 5-fold over compound 1 (Fig. 1).  The phenyl (compound 10) substitution 318 
was not tolerated with LeuRS IC50 values of 28 µM (Fig. 1).  However, it must be noted that 319 
the significant improvements in MIC values for compounds 4, 6 and 11 were not fully 320 
reflected in their IC50 values as determined using an aminoacylation assay with M. 321 
tuberculosis LeuRS, which could be due to the way that OBORT inhibitors indirectly inhibit 322 
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aminoacylation by preventing Ade76 binding to the aminoacylation active site (29). We 323 
therefore decided to measure the direct binding of the compounds to the editing domain using 324 
isothermal titration calorimetry (ITC) and found that the 4-Cl and 4-Br substitutions 325 
significantly enhanced the affinity of the compounds to the M. tuberculosis LeuRS editing 326 
domain (Table 3). The increased affinity is due to a significant gain in the enthalpic 327 
contribution (3.1-4.5 Kcal mol-1), which is consistent with additional favourable interactions 328 
being established by the halogen atoms in the editing site. To confirm whole cell activity was 329 
derived from inhibition of LeuRS we selected 6 M. tuberculosis mutants resistant to 330 
compound 13 and sequenced their leuS gene, while two additional mutants were selected for 331 
whole genome sequencing. All 8 resistant mutants had SNP in their leuS genes and the 332 
mutations were located in the editing domain as expected for OBORT LeuRS inhibitors (13, 333 
24, 29) (Table S2). To further explore interactions at 4-position, we co-crystallised 334 
compounds with 4-Cl and 4-Br substitutions in the presence of AMP and solved the 335 
structures of the ternary complexes at 1.45 and 1.47 Å resolution, respectively (Table S1, Fig. 336 
S1).  The structures showed that the halogenated compounds bind to the editing site without 337 
major structural changes and as predicted, the 4-Cl/Br atoms now occupy the position of the 338 
sulphur in bound methionine (Fig. S2A) allowing van der Waals interactions with the 339 
neighbouring protein atoms (Fig. S2B). These results confirmed the importance of the size 340 
and nature of the substitution at position 4, and agreed well with the in vitro activities and 341 
thermodynamic analysis (Fig. S2C).  342 
We selected the three most potent compounds, 11, 12 and 13, for in vivo murine 343 
pharmacokinetic analysis and we dosed mice both intravenously (IV) and orally (PO). All 344 
three compounds showed improvements in plasma exposure as measured by AUC after oral 345 
administration over compound 2 (Table 4). Therefore, we tested them in a GKO mouse 346 
model of acute TB, which showed all to be very efficacious with the racemate compound 11 347 
having similar efficacy to isoniazid (Fig. 5AB).  In a chronic TB BALB/c mouse model, all 348 
compounds showed good efficacy (Fig. 5C) with compound 14, the (S)-isomer of compound 349 
11, being the most potent.  In addition, we observed that compounds 13 and 14 did not show 350 
any cross-resistance against multidrug-resistant isolates (Table S3).   351 
Inhibition of mitochondrial protein synthesis. Although protein synthesis inhibitors are 352 
validated TB drugs they are associated with some safety concerns, for example 353 
myelosuppression and neuropathy observed with linezolid (16) and deafness induced by 354 
aminoglycosides (12). The similarity between the bacterial and mitochondrial protein 355 
synthesis machinery (2) and their subsequent inhibition of mitochondrial protein synthesis is 356 
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thought to drive these toxicities. Therefore, we tested the ability of compound 14 and some 357 
close analogues to inhibit mitochondrial protein synthesis in the human liver carcinoma cell 358 
line HepG2 (Table 5). The ribosomal protein synthesis inhibitors linezolid, chloramphenicol 359 
and doxycycline inhibited the synthesis of the mitochondrial derived COX1 protein with EC50 360 
values of between 23 and 31 µM, while erythromycin and compounds 12, 13 and 14 had 361 
EC50 values of >150 µM. Although this could be due to poor mitochondrial penetration, it is 362 
interesting to note that human mitochondrial LeuRS is known to be editing defective as it 363 
lacks key conserved amino acid residues in the AMP binding loop and amine binding pocket 364 
(21).   365 
Compound 14 in vitro and in vivo activity.  Since the racemate 11 had similar activity to 366 
isoniazid, which is an in vitro bactericidal compound (8), in the acute GKO mouse model 367 
(Fig. 5B) we tested the enantiomer pure compound 14 for in vitro bactericidal activity over 368 
14 days at 20-fold its MIC (Fig. 6).  The profile for compound 14 was very similar to the 369 
bacteriostatic protein synthesis inhibitor, linezolid, which was different from moxifloxacin a 370 
known bactericidal compound (33).  Therefore, further tests of compound 14 in a murine 371 
chronic TB model (Fig. 7) were performed in parallel with the protein synthesis inhibitor 372 
linezolid.  Compound 14 at 30 mg/kg QD showed good efficacy resulting in a 2.4 log10 373 
reduction in CFU compared with a 2.6 log10 reduction in CFU for 100 mg/kg QD of linezolid. 374 
In order to establish the optimal dosing regimen for compound 14 we tested it in the acute TB 375 
murine model and compared the efficacy from the following dosing regimes, BID, QD and 376 
q48h (Fig. 8). Similar to results in the chronic model, compound 14 was more active at lower 377 
doses than linezolid and dosing every other day (q48h) was as efficacious as QD or even 378 
BID, which suggests that the preliminary pharmacodynamic driver for efficacy was 379 
AUC/MIC. 380 
Resistance and LeuRS inhibitors.  Emergence of resistance during streptomycin 381 
monotherapy (1) and its noted reduction by the addition of p-aminosalicyclic acid (11, 23) 382 
lead to the paradigm of combination TB drug therapy. The current core TB regimen calls for 383 
a four-drug combination of isoniazid, rifampin, ethambutol and pyrazinamide. Although 384 
compound 14 has a lower in vitro resistance frequency than isoniazid (Supplementary Table 385 
7), the emergence of resistance to epetraborole (GSK2251052/AN3365), another 3-386 
aminomethylbenzoxaborole LeuRS inhibitor, in a minority of patients in a complicated 387 
urinary tract infection trial might suggest some caution (24). However, the addition of 388 
trimethoprim to rifampicin, which has a similar resistance problem, in an urinary tract 389 
infection trial demonstrated the benefit of combination therapy in overcoming emergence of 390 
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rifampin-resistant strains (27).  This suggests that the risk from emergence of resistance to 391 
OBORT LeuRS inhibitors will likely be mitigated when used in combination therapy.  392 
Beneficial properties. Since combination therapy necessitates a larger armamentarium than 393 
regular monotherapy, the demonstration for the first time that an oral AARS inhibitor can be 394 
a potent antitubercular adds a potential new tool to fight TB, which is timely noting the recent 395 
onset of TDR-TB. In addition, the combination of low plasma protein binding, molecular 396 
weight (207-285) and logD7.4 (-0.04-0.76), like the frontline TB drugs isoniazid, 397 
pyrazinamide and ethambutol, suggests that this novel chemical class deserves further 398 
optimisation and hopefully progression into clinical trials. 399 
400 
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Table 1. MIC values for compound 1 resistant mutants. 554 
Organism/Mutant
/SNP 
Agar MIC
(µg/mL) 
Organism/Mutant 
/SNP 
Liquid MIC 
(µg/mL) 
M. tuberculosis 
H37Rv 0.6-1.3 
M. smegmatis 
ATCC 700084 1 
RM1leuS Y435C 21 RM1leuSΔ421-462 >256 
RM2leuS S311L 21 RM2leuS A428T 64 
RM3leuS D450Y 21 RM3leuS R435C 8 
RM4leuS S311L 21 RM4leuS A428T 64 
The residues Y435 and D450 stabilize the adduct formed by compound 1 with AMP in the 555 
editing site of M. tuberculosis LeuRS (Figure 4b). The residue S311, like the equivalent E. 556 
coli LeuRS residue (20), interacts with phosphate of Ade76 thus stabilizing the adduct in the 557 
editing site. However, S311 is located at the flexible N-terminal part of our editing domain 558 
construct of M. tuberculosis LeuRS and thus is not visible in the crystal structure (Figure 4b). 559 
SNP = single nucleotide polymorphism, RM = resistant mutant.560 
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Table 2. Compound 1 MIC (µg/mL) against M. tuberculosis Erdman and monoresistant 561 
isolates compared with known standards 562 
Strain Cmp 1 PA-824 RIF INH STR 
M. tuberculosis 
Erdman 
0.127  0.116 0.018 0.244 0.369 
rRIF 0.120  0.128 >4 0.383 0.216 
rINH 0.059  ≤0.063 0.037 >8 0.202 
rSTR 0.113  0.189 0.082 0.344 >16 
r, resistance to RIF = Rifampin, INH= Isoniazid or STR= Streptomycin 563 
564 
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Table 3. Thermodynamic analysis of the interaction between M. tuberculosis LeuRS and 565 
benzoxaborole compounds. 566 
Compound/ 
parameter 
 
 
Kd* 
(µM) 
 
 
ΔGap 
(Kcal mol-1) 
ΔHap 
(Kcal mol-1) 
-TΔSap 
(Kcal mol-1) 
 
 n 
2  3.7  - 7.4 -1.1 -6.3  1.05 
13  0.075  -9.7 -4.2 -5.5  1.19 
11  0.040  -10.0 -5.5 -4.6  1.02 
 
* The error in the thermodynamic binding parameters is about 5% for the apparent binding enthalpy, and 10% 567 
for the apparent binding constant and the number of sites (n). Values in the table are the average of at least 2 568 
independent experiments. 569 
570 
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Table 4. Murine Pharmacokinetic Parameters 571 
*IV Cmp2 Cmp11 Cmp12 Cmp13 Cmp14 
30 15 30 30 30 
Cmax (µg/mL) @ 5 min 8.9 18.0 13.7 13.6 17.1 
CL (mL/h/kg) 2180 328 1119 582 687 
Vss (mL/kg) 2116 968 3805 3142 3221 
MRT (h) 2.1 3.0 3.4 5.4 4.7 
AUC0-∞ (h*µg/mL) 13.8 45.8 26.8 51.6 43.7 
α-t1/2 (hr) [%AUC] 0.06[5] 0.09 [2] 0.11 [7] 0.10 [2] 0.05 [5] 
β-t1/2 (hr) [%AUC] 1.5[95] 2.08 [98] 2.53 [93] 3.83 [98] 3.40 [95] 
#PO (mg/kg) 30 30 30 30 30 
Cmax (µg/mL) 3.4 7.2 5.0 6.4 6.3 
Tmax (h) 0.50 1.00 1.00 0.25 0.50 
AUC0-24 (h*µg/mL) 13.2 35.9 23.8 47.5 57.6 
Terminal t1/2 (h) 1.8 2.7 2.7 3.1 3.6 
Bioavailability (%) 96 39 89 92 100 
Mouse PPB(%) 6 50 16 23 - 
*WinNonlin two-compartment analysis iterative weighting. 572 
#WinNonlin non-compartment analysis with uniform weighing.573 
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 574 
 Table 5.  Mitochondrial protein synthesis inhibition 575 
Compound  
COX1 
EC50 
(µM) 
SDHA 
EC50 
(µM) 
Cell 
Viability 
EC50 
(µM) 
Compound 12  >150 39.5 ± 9.2 23.0 ± 1.4 
Compound 13  >150 20.5 ± 2.1 80.0 ± 5.7 
Compound 14  >150 21.5 ± 6.4 106 ± 37.5 
Linezolid  27.3 ± 10.8 >150 >150 
Chloramphenicol  31.4 ± 23.2 >150 110 ± 14.1 
Doxycycline  23.7 ± 6.4 109 ± 29 118 ± 35.5 
Erythromycin  >150 >150 >150 
COX1 is cytochrome c oxidase, which is a mitochondrial protein that is 576 
synthesized by mitochondrial ribosomes.  SDHA is subunit A of succinate 577 
dehydrogenase complex, which is a mitochondrial protein that is 578 
synthesized by cytoplasmic ribosomes. Janus Green staining was used to 579 
determined cell viability after 7 days. 580 
581 
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 Table 6.  In vitro resistance frequency 582 
Compound  4xMIC 10xMIC 
Compound 14  4.6 x 10-6 
 
3.9 x 10-6 
Isoniazid  ND 
 
1.8 x 10-5 
Moxifloxacin  1.7 x 10-7 
 
1.1 x 10-8 
The MIC values for compound 14, isoniazid and moxifloxacin were 583 
determined on Middlebrook 7H10 agar as 0.2, 0.06 and 0.08 µg/mL, 584 
respectively. 585 
586 
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FIGURE LEGENDS 587 
Figure 1.  In vitro structure-activity relationship. Mtb = M. tuberculosis, NT= not tested. 588 
Figure 2.  Compound 1 resistant mutants bear mutations in the editing domain of LeuRS.  589 
(A) Domain map of M. tuberculosis LeuRS.  (B) Amino acid alignment of part of the editing 590 
domain of LeuRS from M. tuberculosis and M. smegmatis, identical residues are colored in 591 
blue, non-identical residues are colored in red with arrows indicating where the mutations 592 
were found. 593 
Figure 3. In vivo efficacy of compound 2 in a murine GKO (C57BL/6-Ifngtm1ts) model of 594 
acute TB. Oral treatment was started 15 days (Start) after infection with a low dose aerosol of 595 
M. tuberculosis Erdman lux and continued for 9 consecutive daily treatments until day 23 596 
when mice were euthanized on day 24 (End). CFU were determined from lungs (black) and 597 
spleens (grey) and means from five mice for drug treated groups and 6 mice per group for the 598 
untreated controls.  *P < 0.001 by pairwise multiple comparison procedures (Tukey test) 599 
compared to control. 600 
Figure 4. X-ray co-crystal structure of LeuRS with compound 2. (A) Crystal structure of M. 601 
tuberculosis LeuRS editing domain in complex with compound 2 (carbon atoms are colored 602 
in green)-AMP (carbon atoms are colored in magenta). Color code is the same throughout all 603 
figures with blue for nitrogen, red for oxygen, pink for boron, orange for phosphorus, yellow 604 
for sulfur. (B) Zoomed view into the editing site of M. tuberculosis LeuRS showing the 605 
compound 2-AMP adduct and the key residues establishing important hydrogen bonds (red 606 
dashed lines) with only the H-bond from the 3-aminomethyl to M441 being omitted for 607 
clarity. (C) Overlay of the LeuRS editing domain of M. tuberculosis and E. coli in complex 608 
with methionine colored in yellow (PDB: 2AJF). The 3-aminomethyl group of compound 2 609 
mimics the amino group of methionine, including the interaction to the bacterial specific 610 
residue D447.  611 
Figure 5.  In vivo efficacy of compounds 11, 12, 13 and 14 in acute and chronic models of 612 
TB infection. (A) In vivo efficacy in a murine GKO (C57BL/6-Ifngtm1ts) model of acute TB.  613 
Compounds were dosed orally daily for 14 days after 10 days infection (Start) with a low 614 
dose aerosol of M. tuberculosis Erdman. Mean lung CFU were determined from five mice at 615 
End. (B) In vivo efficacy in a murine GKO (C57BL/6-Ifngtm1ts) model of acute TB.  Oral 616 
treatment was started 13 days after infection (Start) with low dose aerosol of M. tuberculosis 617 
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29 
Erdman lux and continued for 9 consecutive daily treatments until day 21 when mice were 618 
sacrificed on day 22 (End). Mean lung CFU were determined from five mice at End. (c) In 619 
vivo efficacy in a murine BALB/c model of chronic TB infection. Compounds were dosed 620 
orally 5 days a week for 4 weeks after infecting with M. tuberculosis Erdman with a low dose 621 
aerosol 21 days prior (Start).  Lung (black) and spleen (grey) CFU were determined from six 622 
mice at End.  **P< 0.01, *P < 0.001 by pairwise multiple comparison procedures (Tukey 623 
test) compared to control. 624 
Figure 6.  M. tuberculosis H37Rv in vitro kill kinetics. Cells were incubated with compounds 625 
at 20-fold their MIC values for different times over 14 days in 10 mL of 7H9 10% (v/v) ADC 626 
and 0.05% (v/v) Tween 80 medium.  The MIC values used in this experiment were as 627 
follows, 0.013 µg/mL, 0.6 µg/mL and 0.06 µg/mL for compound 14, linezolid and 628 
moxifloxacin, respectively.  The mean and the standard deviations of at triplicate cultures of 629 
each point are shown. 630 
Figure 7.  Efficacy of compound 14 in a mouse model of chronic TB infection.  C57 BL/6J 631 
mice were infected with M. tuberculosis H37Rv intratracheally (~102 CFU) and were dosed 632 
once daily for 8 weeks starting 6 weeks after infection. Mice were sacrificed 24 hours after 633 
the last drug administration. Every column represents the mean value +/- SD of 7 mice per 634 
group for untreated and Linezolid treated groups and 3 mice for Compound 14 treated mice.  635 
*P < 0.001 by pairwise multiple comparison procedures (Tukey test) compared to control. 636 
Figure 8.  Efficacy of compound 14 in a mouse model of acute TB infection under different 637 
dosing regimes of once a day (QD), twice a day (BID) or every other day (q48h). C57 BL/6J 638 
mice were infected with M. tuberculosis H37Rv intratracheally (~105 CFU) and were dosed 639 
starting on the following day after infection for 8 days. Only one dose was administered on 640 
day 8 under the BID schedule. Mice were sacrificed at least 24 hours after the last drug 641 
administration. Every dot represents one mouse data point except for Linezolid (mean of 5 642 
mice +/- SD). 643 
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